2018 Promising Scholars Award Program


Residents, students, and fellows are invited to submit a manuscript on the topic, “Tardive Dyskinesia." More in this courtesy post.

Editor's note: This is a courtesy post. The sponsor associated with this announcement is not affiliated with Psychiatric Times.

The 2018 Promising Scholars Award Program, which is jointly sponsored by Neurocrine Biosciences, Inc and the Neuroleptic Malignant Syndrome Information Service (NMSIS), provides a unique opportunity for talented early career psychiatrists to gain experience in scholarly activities and research. Residents, students, and fellows are invited to submit a manuscript on the topic, “Tardive Dyskinesia,” for first- and second-place awards in the amounts of $2500 and $1500, respectively. Two winners will be selected to receive the awards, which will be presented at the Institute for Psychiatric Services: The Mental Health Services Conference, October 2018, in Chicago.

Learning objectives

• Participants will learn the steps necessary to prepare a scientific manuscript for publication

• Participants will review comments by expert referees and learn to incorporate and respond to the peer review process

• Participants will review the evidence related to diagnosis and treatment of tardive dyskinesia

• Participants will be introduced to the spectrum of educational and networking opportunities at national conferences

Instructions for submission

• First author must be a student, resident or fellow

• The manuscript should address specific issues related to the theme of tardive dyskinesia and be no longer than 15 double-spaced typed pages (excluding references and illustrations)

• Literature reviews, case reports, or studies that are original and newly developed or recently published are acceptable

The manuscript and the first author’s curriculum vitae must be submitted by July 1, 2018 to Ms. Dianne Daugherty via email, dianne@mhaus.org. Reviews and feedback will be provided by a panel of academic physicians. The manuscript will be judged on relevance to tardive dyskinesia, originality, scholarship, scientific rigor, valid methodology, clinical significance, and organization. Winners will be announced by August 10, 2018. For additional information, contact dianne@mhaus.org or visit http://www.mhaus.org/nmsis/about-us/what-is-nmsis.


© 2024 MJH Life Sciences

All rights reserved.